The large biotech I worked for explicitly allocated 2% of shares each year to executive comp - new and existing, with some y-t-y variation allowed.

This assumption, along with impacts of other financings, was used in the long range plan in forecasting shares outstanding. I took those presentations to the board and to ratings agencies - neither was offended.

Compare that to what NP is asking, and consider he has to build a "real" company from scratch..

Just my experience, quite a while ago.